INTRODUCTION
============

Gynecomastia is a benign condition characterized by breast growth in males. It develops in association with localized fat deposition and glandular tissue proliferation in the breast. Proliferation of male breast tissue may be seen at any age, and may be uni- or bilateral \[[@ref1]\]. Neyzi *et al*. \[[@ref2]\] reported a prevalence of gynecomastia of 7%. Several factors may be involved in the etiology of gynecomastia. Among these factors, the drug-related gynecomastia was one of the leading causes \[[@ref3]\]. Various medications are capable of causing gynecomastia, including diazepam, haloperidol, phenothiazine and tricyclic antidepressants \[[@ref4]\]. Methylphenidate (MPH), the first-line treatment for attention deficit hyperactivity disorder (ADHD), is effective and well-tolerated. Gynecomastia is a rare side-effect during MPH therapy. To the best of our knowledge, there have been few case reports of the condition developing as a side-effect of MPH \[[@ref5],[@ref6]\]. We report a case of an adolescent boy developing bilateral, dose-dependent gynecomastia during MPH monotherapy.

CASE
====

A 15-year-old boy presented with his mother due to the complaints of symptoms of ADHD including hyperactivity, impulsivity and inattentiveness. Anamnesis taken from the mother revealed that the patient had used the osmotic-release oral system (OROS) MPH (Concerta; Jansen-Cliang Manufacturing LLC., Gurabo, Porto Riko) formulation for ADHD, which he had benefitted from MPH at that time, but that they had discontinued the treatment of their own volition for the previous two years. Since the patient had previously benefited from MPH for ADHD, he was started on OROS MPH (Concerta) at 27 mg/day and invited to follow-up one month later. At follow-up we learned that he had failed to benefit from 27 mg/day OROS MPH (Concerta), and the dosage was raised to 36 mg OROS MPH (Concerta). At follow-up one month subsequently, the patient reported swelling and growth in the breast following dosage enhancement, and stated that this had a psychologically adverse impact on him. The pediatric endocrinology department was then consulted. At consultation, the patient's prolactin was 7.86 ng/ml (normal range, \< 15 ng/ml), and no tenderness or galactorrhea were present. The patient weighed 52 kg (10th−25th percentiles) and was 175 cm in height (10th−25th percentiles). His body mass index was 16.97 kg/m^2^. He denied the use of any drug, herbal product or substance. Bilateral gynecomastia was diagnosed by the endocrinology department, and the drug discontinuation was recommended. OROS MPH (Concerta) therapy was stopped, and the patient was started in atomoxetine (ATX) 50 mg/day. When we re-evaluated his previous history, the same side-effect had previously been observed with 27 mg OROS MPH (Concerta), but that the patient had been reluctant to disclose this at the initial interview due to embarrassment. At one-month follow-up we learned from the family that the breast growth had been reversed, but that the patient's attention problems persisted, that he was short-tempered and irritable, and that he had been involved in arguments with teachers at school. Risperidone 1 mg/day was then added to treatment, and ATX was increased to 60 mg/day. At the subsequent follow-up his irritability had decreased. The patient was monitored with ATX 60 mg/day and risperdal 1 mg/day for a period of one year. He benefited from treatment during that period, and no recurrence of gynecomastia was observed.

DISCUSSION
==========

MPH is a commonly preferred and well-tolerated drug in the treatment of children and adolescents. However, some side-effects may occur during treatment. Commonly reported side-effects during MPH therapy include nausea, lack of appetite, weight loss, and sleep disturbances \[[@ref7]\]. In addition to these widespread side-effects, MPH has also been reported to cause rare side-effects such as skin eruptions \[[@ref8],[@ref9]\], inappropriate sexual behavior \[[@ref10]\], obsessive compulsive symptoms \[[@ref11]\], hallucinations \[[@ref12]\], painful muscle cramps \[[@ref13]\], hyperhidrosis \[[@ref14]\] and excessive and frequent menstrual bleeding \[[@ref15]\].

Only a few reports of MPH-induced gynecomastia have appeared in the literature. Coşkun *et al*. \[[@ref6]\] reported gynecomastia during OROS MPH (Concerta) use in a boy of 10 \[[@ref6]\]. Ensat *et al*. \[[@ref5]\] reported unilateral gynecomastia associated with MPH use in a six-year-old boy. The case of Coşkun *et al*. \[[@ref6]\] used paroxetine and MPH therapy, and gynecomastia occurred six months after dosage increase. No regression in gynecomastia occurred after the drug discontinuation. Similarly, no regression was observed after discontinuation in the case of Ensat *et al*. \[[@ref5]\] In our case, however, MPH-related gynecomastia improved after drug stoppage. In a review study, Bowman *et al*. \[[@ref3]\] also reported that drug-related gynecomastia frequently improves after stoppage. From that perspective, our case is in line with previous reports. In our case, gynecomastia emerged immediately after the drug dosage was increased. In the two other cases, the condition emerged independently of dosage and six months after dosage increase. In our case, only the OROS MPH (Concerta) formulation was being used when gynecomastia developed. Our case was evaluated with the Naranjo Adverse Drug Reaction Probability Scale (NADRPS). On this scale, a score ≥ 9 is regarded as definite, a score between 5 and 8 is considered probable, a score between 1 and 4 is considered possible, and a score of 0 is regarded as doubtful \[[@ref16]\]. Our case's NADRPS score was 9. Gynecomastia is a physically and socially disturbing psychosocial problem for adolescents with adverse impacts on quality of life and self-esteem. Although gynecomastia had developed previously in our patient in association with the same medication, he was too embarrassed to mention this at interview. Arslan *et al*. \[[@ref17]\] revealed that gynecomastia impaired body perception, self-esteem, and psychosocial functionality in adolescents. Nuzzi *et al*. \[[@ref18]\] also reported adverse psychosocial impacts of gynecomastia in adolescents.

The pathophysiological mechanism by which MPH gives rise to gynecomastia is uncertain. Various mechanisms have been proposed in the development of the condition, including increased estrogen production (increased concentrations in serum and tissue), decreased androgen production or effects thereof, and hypersensitive breast tissue \[[@ref19],[@ref20]\]. Impaired hormone balance plays a key role in all these hypotheses. Low testosterone to estradiol and adrenal androgens to estradiol ratios have been determined in cases of prepubertal gynecomastia \[[@ref21]\]. In an animal study of the androgenic effects of MPH in rats, Adriani *et al*. \[[@ref22]\] reported a marked decrease in testosterone concentrations with MPH. Testosterone levels decreased significantly, by 40%, in rats treated with MPH compared to control animals. This study suggests that a decreased androgen effect associated with decreased testosterone levels may be responsible for MPH-induced gynecomastia.

Treatment in our case was switched to ATX following the development of MPH-related gynecomastia. The patient was followed-up for a one-year period after switching to ATX, and no gynecomastia was observed. To the best of our knowledge, there have been no reports of ATX-related gynecomastia. We therefore elected to use ATX, and no problems were encountered in management of treatment.

Although MPH-related gynecomastia is a rare situation, it developed following an increase in MPH dosage in our case. Clinicians should therefore consider the possibility of gynecomastia with MPH therapy. It will also be beneficial for clinicians to consider ATX as an alternative in the management of MPH-related gynecomastia.
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